SCEMBLIX is tough on Ph+ CML in chronic phase.
SCEMBLIX is a tyrosine kinase inhibitor (TKI) that is tough on Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
And it works differently than other TKIs that treat the disease. SCEMBLIX is the first and only TKI that is thought to bind to a different site (myristoyl pocket) within the abnormal protein that causes Ph+ CML in chronic phase. Ask your doctor about SCEMBLIX.
Interested in saving on SCEMBLIX?
Learn about resources for eligible patients who have been prescribed SCEMBLIX
Considering SCEMBLIX?
Sign up for information about the medication and the disease